

# Inflammation and Leukocyte Migration

# Objectives

- Overview of the inflammatory process: initiation, inflammation, resolution, benefits and liabilities
- Major constituents
- Clinically relevant inflammatory processes
- Control of inflammation

# Introduction

- “Inflame” – to set fire
- Inflammation is “A dynamic response of vascularised tissue to injury.”
- Inflammation: Local defense and protective response against cell injury or irritation or local vascular and cellular reaction, against an irritant.
- It is a protective response.
- It serves to bring defense & healing mechanisms to the site of injury.
- Inflammation is designated by adding the suffix (itis) to the end of the name of the inflamed organ or tissue.

# Etiology

- Microbial infections: bacterial, viral, fungal, etc.
- Physical agents: burns, trauma--like cuts, radiation
- Chemicals: drugs, toxins, or caustic substances like battery acid.
- Immunologic reactions: rheumatoid arthritis.

# Types

- Time course
  - Acute inflammation: Less than 48 hours
  - Chronic inflammation: Greater than 48 hours (weeks, months, years)
- Cell type
  - Acute inflammation: Neutrophils
  - Chronic inflammation: Mononuclear cells (Macrophages, Lymphocytes, Plasma cells).

# Cardinal Signs of Inflammation

- Redness : Hyperemia.
- Warm : Hyperemia.
- Pain : Nerve, Chemical mediators.
- Swelling : Exudation
- Loss of Function: Pain




# Pathogenesis

- The vascular & cellular responses of inflammation are mediated by chemical factors (derived from blood plasma or some cells) & triggered by inflammatory stimulus.
- Three main processes occur at the site of inflammation, due to the release of chemical mediators :
  1. Increased blood flow (redness and warmth).
  2. Increased vascular permeability (swelling, pain & loss of function).
  3. Leukocytic Infiltration.

# 1. Local Vascular Changes

- Initial temporary vasoconstriction for few seconds.
- Active vasodilatation of arterioles and capillaries by chemical mediators like histamine and passive dilatation of venules.
- Slowing of the circulation: outpouring of albumin rich fluid into the extravascular tissues results in the concentration of RBCs in small vessels and increased viscosity of blood (stasis).
- Pavementation: the margination of leukocytes. Neutrophils become oriented at the periphery of vessels and start to stick.



## 2. Leukocyte Exudation


- Leukocytes (PMN's , Mphages, lymphocytes, mainly T) circulate in the blood, but often do their work in tissues.
- For T and B cells, circulation increases the chances that you'll meet your antigen.
- For both to do their jobs, however, you often have to leave the blood to enter either the lymph node or the site of damage.
- Once at the site of damage, you want to kill microbes, control the damage, and repair it.

# Leukocytes Extravasation

- Neutrophils are usually the first cells to move to site of infections or inflammations
- Neutrophils extravasation involves 4 main stages:
  1. Rolling: mediated by selectines
  2. Activation by chemoattractant stimulus
  3. Arrest and adhesion mediated by Integrins binding to Ig-family members
  4. Transendothelial migration


# 1. Rolling

- In this step leukocytes attached loosely to the endothelium by low affinity selectins-carbohydrate interaction
- This interaction tether the leukocyte briefly to endothelium, but the shearing force of blood flow detached the cells soon
- Selectine molecules on another endothelial cells tether the leukocytes again; this process is repeated so the cells trumble over the endothelium “rolling”




## 2. Activation

- The process of rolling slow the cells enough to allow interactions between chemokines on the endothelium surface and receptors on leukocytes
- This binding leads to signal transduction events results in change in confirmation and clustering of integrins on leukocytes




# 3. Firm Adhesion

- Binding of leukocytes to endothelium and slowing down of leukocytes allow binding of other adhesion molecules including integrins which leads to firm adhesion
- This allowed the leukocytes to binds more tightly to endothelium and it become less likely that blood force will detach them




# 4. Transendothelial Migration

- Leukocyte then squeezes in between two neighboring endothelial cells without disrupting the integrity of these cells
- This is accomplished by binding of platelet endothelial cell adhesion molecule 1 (PECAM-1) on leukocyte with PECAM-1 on endothelial cells



# Lymphatics in Inflammation:

- Lymphatics are responsible for draining edema.
- **Edema:** An excess of fluid in the interstitial tissue or serous cavities; either a transudate or an exudate
- **Transudate:** an ultrafiltrate of blood plasma
  - permeability of endothelium is usually normal.
  - low protein content (mostly albumin)
- **Exudate:** A filtrate of blood plasma mixed with inflammatory cells and cellular debris.
  - permeability of endothelium is usually altered
  - high protein content.
- **Pus:** A purulent exudate: an inflammatory exudate rich in leukocytes (mostly neutrophils) and parenchymal cell debris.



# Function of Inflammatory Exudates

- **Dilute** the invading microorganism and its toxins.
- Bring **antibodies** through the plasma to the inflamed area.
- Bring **leukocytes** that **engulf** the invading microorganisms.
- Bring **fibrinogen** through the plasma, which is converted, to fibrin mesh, helping in **trapping** the microorganism and localize the infection

# Inflammatory Mediators:

- Chemical substances synthesised or released and mediate the changes in inflammation.
  1. Histamine by mast cells - vasodilatation.
  2. Prostaglandins – Cause pain & fever.
  3. Bradykinin - Causes pain.
- Cytokines including TNF, IL1, IL6, IL8
- Lipid mediators: prostaglandins, leukotrienes, and platelet activation factor

# Cytokines and Inflammation

- Macrophages or DCs stimulated via innate immune receptors make pro-inflammatory cytokines, especially TNF (Tumor necrosis factor), IL-1, and IL-6
- TNF and IL-1 signal to endothelial cells to make them:
  - Leaky to fluid (influx of plasma; containing antibodies, complement components, etc.)
  - Sticky for leukocytes, leading to influx of first neutrophils, later monocytes, lymphocytes
  - IL-6 promotes adaptive immune responses and has systemic effects (“acute phase response” of liver, including C-reactive protein or CRP; levels used clinically as an indication of systemic inflammation)

# Negative Regulation of Inflammation

- Cells responding to innate stimuli stop making inflammatory mediators after short time period and convert to making anti-inflammatory lipids
- Killing the infectious agent and removal of the dead cells, debris, crystals, will stop stimulation of incoming inflammatory cells
- Systemic elevation of inflammatory cytokines (esp. IL-1) induce production of glucocorticoids, which are anti-inflammatory
- Regulatory T cells are also anti-inflammatory, both by blocking effector T cells and by inhibiting innate cells

# Inflammation Outcomes

1. Abscess formation
2. Progression to chronic inflammation
3. Resolution--tissue goes back to normal
4. Repair--healing by scarring or fibrosis
5. Spread through lymphatics or blood or stream

# Suppurative or Purulent Inflammation



- **Pus:** thick fluid containing viable and necrotic polymorph and necrotic tissue
- **1. Localized:** ex. Abscess: Abscess is the localized collection of pus, commonly seen solid block of tissue - Example: dermis, liver, kidney, brain etc. Pus consists of partly or completely liquefied dead tissue mixed with dead or dying neutrophils and living or dead bacteria, formed of 3 zones
  - Small abscess is called boil or furuncle (الدمل )
  - Large one carbuncle
  - Fistula
- **2. Diffused:** Spreading of pus to adjacent areas e.g. cellulites occurring in subcutaneous tissue . Usually caused by streptococci.

# Anti-Inflammatory Therapeutics

- **NSAIDs**: inhibitors of inflammation and fever (block prostaglandin synthesis)
- **Glucocorticoids** are also potent anti-inflammatory drugs
- Agents that **block TNF** are effective in treating rheumatoid arthritis, Crohn's disease, etc.
- Agents that **block IL-1** are less effective for these diseases but are useful for some genetic inflammatory diseases (and are currently in clinical trials for more common conditions)